Work

Emerging Targeted Therapies in Heart Failure: Molecular Modulators, SGLT2 Inhibitors, and Novel Drug Delivery Systems

Year: 2026
Type: article
Abstract: Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, particularly among the elderly population. This review discusses novel targeted therapies to alter the progression of the disease rather than just reducing symptoms. Developments have been classified into three domains: molecular modulators, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and new drug delivery systems. Molecular therapies such as SERCA2a gene therapy, histone deacetylase (HDAC) inhibitors, and anti-fibrotic drugs such as TGF-β and galectin-3 inhibitors are aimed at central pathophysiological pathways such as calcium mishandling, epigenetic remodelling, and myocardial fibrosis. The first developed SGLT2 inhibitors were designed to treat diabetes and they have shown consistent cardiovascular benefits across all HF phenotypes through various mechanisms, e.g., augmented myocardial energetics and reduced inflammation. Advanced delivery systems like nanoparticles, exosomes, hydrogels and CRISPR-Cas9 have the most precision, targeting and persistence of therapeutic effect. The review further highlights future directions, including multimodal therapeutic strategies, genomic-driven precision medicine, and artificial intelligence–assisted treatment planning. Despite these promising advancements, significant challenges remain, including issues related to clinical translation, accessibility, and long-term safety. This evolving landscape underscores a shift toward individualized and regenerative approaches in heart failure management.
Author: Santhosh S
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7216632897
FWCI:
Cites: 44
Cited by:
Related to: 10